Although IGFBP7 expression has previously been proposed as a serum biomarker for bladder cancers [60], whether methylation-dependent mechanisms also regulate IGFBP7 expression in MPM, and to the extent its serum levels could be a useful biomarker in MPM have yet to be addressed. The gene discussed is IGFBP7; the disease is urinary bladder carcinoma.